Kronos Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRON research report →
About the company
Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity.
- CEO
- Deborah A. Knobelman
- IPO
- 2020
- Employees
- 8
- HQ
- San Mateo, CA, US
Price Chart
- Market Cap
- $53.65M
- P/E
- -0.62
- P/S
- 5.45
- P/B
- 0.60
- EV/EBITDA
- 0.10
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -943.21%
- Net Margin
- -874.08%
- ROE
- -69.80%
- ROIC
- -80.16%
- Revenue
- $9.85M · 56.62%
- Net Income
- $-86,079,000 · 23.60%
- EPS
- $-1.43 · 26.67%
- Op Income
- $-92,887,000
- FCF YoY
- 17.44%
- 52W High
- $1.46
- 52W Low
- $0.65
- 50D MA
- $0.80
- 200D MA
- $0.90
- Beta
- 1.64
- Avg Volume
- 855.96K
Get TickerSpark's AI analysis on KRON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | Belldegrun Arie | sell | 20,600 |
| Jun 20, 25 | Belldegrun Arie | other | 679,575 |
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | Belldegrun Arie | sell | 34,000 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | other | 263,750 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 297,186 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 400,000 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 570,868 |
| Jun 20, 25 | BISCHOFBERGER NORBERT W | sell | 699,800 |
Our KRON coverage
Recent articles, reports, and earnings notes.
No research on KRON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KRON report →Similar companies
Peers in the same neighborhood.